Do you preferentially avoid use of piperacillin-tazobactam for empiric anti-pseudomonal coverage in hospitalized patients due to risk of nephrotoxicity?

Do you preferentially avoid use of piperacillin-tazobactam for empiric anti-pseudomonal coverage in hospitalized patients due to risk of nephrotoxicity?

• I do avoid use of piperacillin-tazobactam given risk of nephrotoxicity
• I only avoid use of piperacillin-tazobactam if patient will be concurrently receiving vancomycin
• I use piperacillin-tazobactam, even if concurrently receiving vancomycin, but only if used together for <72 hours
• I use piperacillin-tazobactam, even if concurrently receiving vancomycin for >72 hours
• Other